Abstract:BACKGROUND: Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis. Both cetuximab and endostatin have been found to reduce the expression of endothelial-stimulating growth factors such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8. However, the effects of cetuximab alone or in combination with endostatin on human lung adenocarcinoma cell growth remain unclear.OBJECTIVE: The aim of this study was to evaluate the cellular and molecular effects of cetuximab alone and in combination with endostatin on human lung adenocarcinoma cell lines H1299, SPC-A1, and H460 in vitro.METHODS: The epidermal growth factor receptor (EGFR) status of a panel of human lung adenocarcinoma cell lines was characterized using Western blot analysis. We used a modified tetrazolium salt assay to evaluate the growth-inhibitory effects of cetuximab and endostatin alone and in combination on the cell lines. We also determined the effects of these 2 drugs on VEGF and IL-8 expression using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Cells were treated for 4 days with cetuximab 12.5 mu g/mL, endostatin 25 mu g/mL, or cetuximab 12.5 mu g/mL + endostatin 25 mu g/mL. Untreated cells cultured for 4 days served as controls.RESULTS: EGFR expression in the HI 299 cells was higher than in the SPC-A1 and H460 cells. Varying concentrations of cetuximab alone were associated with a significant growth-inhibitory effect on all 3 cell lines in a dose-dependent manner after 4 days of exposure compared with controls (all, P < 0.05). Compared with controls, varying concentrations of endostatin alone were not associated with significant inhibition of cell growth in any of the 3 cell lines. The inhibitory ratio of cetuximab + endostatin at varying concentrations was significantly greater than that of cetuximab alone (all, P < 0.05). On ELISA, either drug alone was associated with significant reductions in secreted VEGF and IL-8 in the H1299, SPC-A1, and H460 cell lines (all, P < 0.05), with the exception of IL-8 concentration in the H460 cells. Mean (SD) VEGF expression with combination treatment in the H1299 and SPC-A1 cell lines (687 [21] and 629 [23] pg/mL, respectively) was significantly lower than with cetuximab alone (878 [31] and 708 [20] pg/mL; both, P < 0.001); in the H460 cell line, combination treatment was not associated with a significant further reduction in VEGF expression. IL-8 concentrations with cetuximab in the H1299, SPC-A1, and H460 cell lines were 628 (20), 484 (29), and 532 (28) pg/mL, respectively, while the IL-8 concentrations with the combination treatment were 516 (20), 480 (18), and 467 (30) pg/mL. An enhanced effect of endostatin on IL-8 was observed in the H1299 and H460 cell lines (P < 0.001 and P = 0.018, respectively); however, no enhanced effect in the SPC-A1 line was observed. Similar results for VEGF and IL-8 expression were found using Western blot analysis.CONCLUSIONS: The results from this in vitro study suggest that cetuximab treatment might both inhibit human lung adenocarcinoma cell line growth and reduce the expression of VEGF and IL-8, which are the biomarkers of angiogenesis. Endostatin was not associated with inhibition of human lung adenocarcinoma cell line growth directly. Findings with the combination of cetuximab + endostatin suggest that endostatin might enhance the antiangiogenic and antitumor activity of cetuximab through an apparent effect on VEGF expression and, to a lesser degree, on IL-8 expression. (Curr Ther Res Clin Exp. 2009;70:116-128) (C) 2009 Excerpta Medica Inc.

EP regimen combined with recombinant human vascular endostatin (Endostar) inhibits the proliferation of small-cell lung cancer cell Line NCI-H446 and promotes the apoptosis

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Recombinant human endostatin combined carboplatin plus etoposide for advanced small-cell lung cancer.

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Radiosensitization of Recombinant Human Endostatin in Human Lung Squamous Cancer Cells in Vitro

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Influence of Different Drug Delivery Methods for Endostar Combined with a Gemcitabine/cisplatin Regimen in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Randomized Phase Ii Study of Recombinant Human Endostatin in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer (Nct00912392).

P2.02-025 Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma.

[Efficacy of Endostar Combined with Chemotherapy in Multi-Cycle Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Synergistic Effect of Endostatin and Cisplatin on Calu-6 Lung Cancer Cells

Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diag-nosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF

Antineoplastic effects of Endostar combined with combretastatin A4 phosphate in vitro

Clinical Efficiency of Rh-Endostatin Combined with Vincristine and Cisplatin in the Treatment of Non-Small Cell Lung Cancer

The Effects of Cetuximab Alone and in Combination with Endostatin on Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Lung Adenocarcinoma Cells

The dose and time factors on synergistic effects of the combination of endostar and radiation against hepatic carcinoma xenografts in mice

Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model

Therapeutic Observation of Endostar Combined with Cisdiammi Dichloride Platinum on Non-Small Cell Lung Cancer with Malignant Pleural Effusion